BC Week In Review | Aug 18, 2017
Clinical News

Valeant expects to resolve manufacturing issues after second Vyzulta CRL

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said that the CGMP inspection issues identified at its Bausch + Lomb manufacturing facility in Tampa, Fla., will soon be “satisfactorily resolved.” Earlier this month, Valeant received a second...
BC Week In Review | Jul 25, 2016
Clinical News

Trabodenoson/latanoprost: Phase II started

Inotek began a double-blind, placebo-controlled, U.S. Phase II trial to compare once-daily trabodenoson/latanoprost given as a single eye drop in both eyes for 8 weeks vs. 0.0025% or 0.005% topical latanoprost in about 165 patients...
BC Week In Review | Apr 11, 2016
Company News

Ono Pharmaceutical, Santen deal

Ono granted Santen exclusive, worldwide rights to develop and commercialize ONO-9054 . Ono will receive an undisclosed upfront payment and is eligible for milestone payments and royalties. ONO-9054, a prostaglandin F (FP) receptor (PTGFR) and prostaglandin...
BC Week In Review | Sep 29, 2014
Clinical News

Vesneo: Phase III data

Top-line data from the double-blind, international Phase III APOLLO and LUNAR trials in a total of 840 patients with open-angle glaucoma or ocular hypertension showed that once-daily Vesneo met the primary endpoint in both trials...
BC Innovations | Jun 5, 2014
Targets & Mechanisms

De-stressing glaucoma

Glucocorticoids are standard of care for a host of allergic and inflammatory eye conditions, but they elevate intraocular pressure about a third of the time and can result in secondary open-angle glaucoma. A chemical chaperone...
BC Week In Review | Aug 12, 2013
Clinical News

Latanoprostene bunod: Phase III started

NicOx disclosed in its 2Q13 earnings that Bausch + Lomb began the open-label, Japanese Phase III JUPITER trial to evaluate once-daily 0.024% latanoprostene bunod for 1 year in about 130 patients with open-angle glaucoma or...
BC Week In Review | Aug 12, 2013
Clinical News

Latanoprostene bunod: Phase I started

Bausch + Lomb began the open-label, Japanese Phase I KRONUS trial to evaluate once-daily 0.024% latanoprostene bunod for 14 days in about 24 healthy male volunteers. Bausch + Lomb has exclusive, worldwide rights to latanoprostene...
BC Week In Review | Feb 4, 2013
Clinical News

Latanoprostene bunod: Phase III started

Bausch + Lomb began the double-blind, international Phase III LUNAR trial to compare once-daily latanoprostene bunod vs. twice-daily timolol for 3 months in about 393 patients with glaucoma and ocular hypertension. Bausch + Lomb has...
BC Week In Review | Feb 4, 2013
Clinical News

Latanoprostene bunod: Phase III started

Bausch + Lomb began the double-blind, international Phase III APOLLO trial to compare once-daily latanoprostene bunod vs. twice-daily timolol for 3 months in about 393 patients with glaucoma and ocular hypertension. Bausch + Lomb has...
BC Week In Review | Jan 21, 2013
Clinical News

PDC31: Phase I data

A Phase I trial in healthy women with primary dysmenorrhea showed that PDC31 dose-dependently relieved pain and reduced intrauterine pressure. PDC31 was well tolerated with no dose-limiting toxicities (DLTs) reported. PDC said it is in...
Items per page:
1 - 10 of 27